21
Participants
Start Date
November 30, 2009
Primary Completion Date
September 30, 2011
Study Completion Date
September 30, 2011
liraglutide
Increasing dose for self-injection subcutaneously (under the skin) daily over 5 weeks (0.3 - 1.8 mg)
placebo
Increasing dose for self-injection subcutaneously (under the skin) daily over 5 weeks (0.3 - 1.8 mg)
liraglutide
Increasing dose for self-injection subcutaneously (under the skin) daily over 3 to 4 weeks (0.6 - 1.8 mg).
placebo
Increasing dose for self-injection subcutaneously (under the skin) daily over 3 to 4 weeks (0.6 - 1.8 mg).
Novo Nordisk Investigational Site, Brussels
Novo Nordisk Investigational Site, Ljubljana
Novo Nordisk Investigational Site, Pittsburgh
Novo Nordisk Investigational Site, Philadelphia
Novo Nordisk Investigational Site, Louisville
Novo Nordisk Investigational Site, Toledo
Novo Nordisk Investigational Site, Cleveland
Novo Nordisk Investigational Site, Cincinnati
Novo Nordisk Investigational Site, Iowa City
Novo Nordisk Investigational Site, Dallas
Novo Nordisk Investigational Site, Aurora
Novo Nordisk Investigational Site, Los Angeles
Novo Nordisk Investigational Site, Cypress
Novo Nordisk Investigational Site, Los Angeles
Novo Nordisk Investigational Site, Kansas City
Novo Nordisk Investigational Site, Memphis
Novo Nordisk Investigational Site, Birmingham
Novo Nordisk Investigational Site, Manchester
Novo Nordisk Investigational Site, Nottingham
Novo Nordisk Investigational Site, Sheffield
Lead Sponsor
Novo Nordisk A/S
INDUSTRY